

C13
Claim 12 (twice amended) The method of claim 1, wherein the administering is at least during an entire period when the horse is or is suspected to be under conditions which are stressful or which increase the risk of formation of ulcers.


C14
Claim 15 (amended) The method of claim 14, wherein the effective dose is about 50% of usual the for the treatment of ulcers in a horse.

C15
Claim 19 (twice amended) The method of claim 17 wherein the formulation is a pharmaceutical composition for oral administration comprising a proton pump inhibitor, a thickening agent, a basic agent, and a hydrophobic, oily liquid vehicle.



Please add the following claims:

C16
--21. A method for the prevention of gastric ulcers prior to the occurrence of gastric ulcer conditions in a mammal comprising administering an effective amount to prevent gastric ulcers of a proton pump inhibitor to the mammal in need thereof prior or during periods of stress, training, transportation, change in environment or pregnancy.


22. The method of claim 21 wherein the proton pump inhibitor is a compound of the formula



wherein R₆ is



or





where R¹ and R³ are independently selected from the group consisting of lower alkyl, lower alkoxy and halogen, R² is selected from the group consisting of alkyl, lower alkoxy-lower alkoxy, lower fluoroalkoxy and




R⁴ and R⁵ are independently selected from lower alkyl


A is



or




R^6 and R^7 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, lower fluoroalkoxy, lower fluoroalkyl, halogen,





wherein R^8 is lower alkyl or lower alkoxy.

23. The method of claim 22 wherein the proton pump inhibitor is




24. The method of claim 22 wherein the proton inhibitor is selected from the group consisting of







Pantoprazole,



E-3310,



Leminoprazole.



S-4216.

esomeprazole, rabeprazole and Y-81149.

25. The method of claim 21, wherein the administration is periodic.
26. The method of claim 25, wherein the administration is daily.
27. The method of claim 21, wherein the administration is at least during an entire period of stress, training, transportation, change in environment, or pregnancy.
28. The method of claim 21, wherein the effective amount of proton pump inhibitor of 0.1 to 8 mg per kilogram of body weight.
29. The method of claim 21, wherein the effective amount is a dose equal to or less than the usual doses for the treatment of ulcers in the mammal.
30. The method of claim 29, wherein the effective dose is about 50% of the usual dose for the treatment of ulcers in the mammal.
31. The method of claim 21, wherein the proton pump inhibitor is in a formulation for controlled release.

32. The method of claim 21, wherein the proton pump inhibitor is in a formation for oral delivery.

C6 cont 33. The method of claim 32, wherein said formulation is selected from the group consisting of oral solutions, oral suspension, feed premix, pastes, gels, powder, granules, tablets, capsules or boli.

REMARKS

The present amendment is being filed in order to correct the claims in the last amendment and to add claims 21 to 33.

The claims in application are now claims 1 to 19 and 21 to 33, all other claims having been cancelled. It should be noted that in the last amendment, reference was made to claims 21 to 33 but they were inadvertently omitted therefrom. The additional filing fee for the new claims was submitted with the amendment of December 18, 2002.